<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognostic factors in patients with renal cell carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognostic factors in patients with renal cell carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognostic factors in patients with renal cell carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Toni K Choueiri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. (See  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma"</a>.)</p><p>Surgical resection of localized RCC can be curative, but up to one-third of patients eventually recur. In addition, approximately 15 percent of patients with RCC present with locally advanced or metastatic RCC, for which surgery is noncurative. The natural history of disease for patients with advanced or metastatic RCC can vary widely from a few months to many years depending on the clinical, pathologic, laboratory, and radiographic features of the disease. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p>The factors affecting prognosis in patients with RCC will be reviewed here. An overview of the approach to treatment is presented separately. (See  <a class="medical medical_review" href="/z/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ANATOMIC EXTENT OF DISEASE</span><span class="headingEndMark"> — </span>The 2017 (eighth edition) tumor, node, metastasis (TNM) staging system is used to assess the anatomic extent of disease and define prognostic stage groups  (<a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. The anatomic extent of disease is the most consistent factor that influences prognosis in patients with renal cell carcinoma (RCC  (<a class="graphic graphic_figure graphicRef59133" href="/z/d/graphic/59133.html" rel="external">figure 1</a>)). (See  <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'TNM staging system'</a>.)</p><p class="headingAnchor" id="H1056314655"><span class="h2">Stage I/II</span><span class="headingEndMark"> — </span>Patients with stage I RCC have a five-year survival rate over 90 percent in most contemporary series. The survival rate may be slightly lower for patients with stage II disease, with reported five-year survival rates ranging from 75 to 95 percent.</p><p>Patients with stage I or II RCC that invades the urinary collecting system appear to have a significantly worse prognosis [<a href="#rid2">2</a>]. In a multivariate analysis of a series of 1124 cases of RCC, the 10-year survival rates for patients with T1 or T2 primary lesions that had invaded the urinary collecting system were 43 and 41 percent, respectively (hazard ratio 3.2, 95% CI 1.4-7.1).</p><p class="headingAnchor" id="H1056314662"><span class="h2">Stage III</span><span class="headingEndMark"> — </span>The reported five-year survival rate for patients with stage III RCC who undergo nephrectomy ranges from 59 to 70 percent. There are conflicting data about whether extension into the perinephric fat (T3a) alone adversely affects prognosis. Two large studies could not demonstrate a difference when T3a primary tumors were compared with comparably sized T1 and T2 primary tumors [<a href="#rid3">3,4</a>]. By contrast, involvement of the perinephric fat remained a prognostic factor in two other series [<a href="#rid5">5,6</a>]. Among patients with T3a disease, the size of the primary tumor remains a prognostic factor (10-year survival rates of 77, 54, and 46 percent for tumors &lt;4, 4 to 7, and &gt;7 cm, respectively) [<a href="#rid5">5</a>].</p><p>Patients with involvement of the renal vein or inferior vena cava are included in the group with stage III RCC. Although some early studies did not identify an adverse impact of renal vein involvement on prognosis [<a href="#rid7">7,8</a>], other reports found that the extent of vena cava invasion and the anatomic location of the tumor thrombus were important prognostic factors [<a href="#rid9">9,10</a>]. The extent of venous involvement is recognized as a prognostic factor in the eighth edition of the American Joint Committee on Cancer (AJCC) TNM system, with T3a tumors having tumor invasion of the renal vein or its branches, T3b tumors having gross involvement of the inferior vena cava below the diaphragm, and T3c lesions having tumor invading the wall of the inferior vena cava or grossly extending into the inferior vena cava above the diaphragm.</p><p>In addition, invasion of the urine collecting system also appears to be a prognostic factor in patients with stage III RCC. In a series of 303 cases with stage III disease, multivariate analysis found that patients with urine collecting system invasion had significantly worse disease-specific and overall survival compared with those without invasion (five-year rates 34 versus 59 percent and 30 versus 52 percent, respectively) [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1056314683"><span class="h2">Stage IV</span><span class="headingEndMark"> — </span>Overall survival for patients with stage IV disease has improved in the contemporary era of immunotherapy and targeted therapy. When cytokines were the predominant systemic therapies for these patients, median overall survival was initially a little over one year. In subsequent studies of patients receiving either targeted therapies (such as <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> or <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a>) or checkpoint inhibitor immunotherapy (with <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a> plus <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>), median overall survival was over two years (approximately 28 months) [<a href="#rid12">12-14</a>] and almost five years (56 months), respectively [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">HISTOPATHOLOGY</span></p><p class="headingAnchor" id="H1056314835"><span class="h2">Tumor type</span><span class="headingEndMark"> — </span>Whether the tumor subtype (ie, clear cell versus papillary or chromophobe carcinoma) affects prognosis is controversial. A multi-institution study failed to identify a prognostic difference in over 4000 patients when tumor, node, metastasis (TNM) stage, histologic grade, and performance status were considered in a multivariate analysis [<a href="#rid16">16</a>]. In contrast, multivariate analyses of single-institution series from the Mayo Clinic and from Memorial Sloan Kettering Cancer Center (MSKCC) including 3062 and 1668 patients, respectively, both found that patients with clear cell histology had significantly poorer cancer-specific survival [<a href="#rid17">17,18</a>].</p><p>Some less common variants, including collecting duct carcinomas, renal medullary carcinomas, and any histology with sarcomatoid or rhabdoid features, are considered more aggressive and are associated with a shorter survival [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H1056314828"><span class="h2">Tumor grade</span><span class="headingEndMark"> — </span>Histologic grade is an independent factor correlating with survival [<a href="#rid20">20-25</a>]. Multiple systems are used to grade renal cell carcinoma (RCC), of which Fuhrman grade is the most widely used [<a href="#rid23">23-25</a>]. In one report, the five-year survival rates based upon tumor grade were 89, 65, and 46 percent for tumors of histologic grade 1, 2, and 3 to 4, respectively [<a href="#rid20">20</a>]. </p><p>The International Society of Urological Pathology (ISUP) Consensus Conference tumor grading system is also available, in addition to recommendations for other prognostic factors related to renal tumors [<a href="#rid26">26</a>]. In this system, ISUP grade 1 tumors were defined as having inconspicuous/absent nucleoli at ×400 magnification; for ISUP grade 2 tumors, nucleoli should be distinctly visible at ×400, though invisible at ×100 magnification; and for ISUP grade 3 tumors, nucleoli should be visible at ×100 magnification. ISUP grade 4 tumors are the ones showing extreme nuclear pleomorphism, clumping of chromatin, or sarcomatoid/rhabdoid dedifferentiation [<a href="#rid26">26</a>]. </p><p class="headingAnchor" id="H298307"><span class="h2">Tumor necrosis</span><span class="headingEndMark"> — </span>Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC and should be routinely reported. It is also part of several integrated staging systems, such as the Stage, Size, Grade, and Necrosis (SSIGN) score [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FACTORS</span><span class="headingEndMark"> — </span>In addition to the anatomic extent of disease, clinical factors can influence survival. Adverse prognostic signs include a poor performance status, the presence of symptoms and/or paraneoplastic syndromes (eg, anemia, hypercalcemia, thrombocytosis, fever, weight loss), and obesity [<a href="#rid21">21,29-34</a>]. Although younger patients (ie, 20 to 40 years old) are more likely to be symptomatic at presentation, their outcome may be slightly better due to a lower incidence of nodal involvement [<a href="#rid35">35</a>].</p><p>Multiple models have been developed to integrate the information from anatomic staging with histopathology and clinical prognostic parameters [<a href="#rid36">36-40</a>]. Nevertheless, validation studies show a low predictive ability of these models, with several only marginally outperforming tumor, node, metastasis (TNM) staging [<a href="#rid41">41</a>].</p><p>A validated prognostic model has been the University of California, Los Angeles (UCLA) integrated staging system (UISS) (<a class="calc calc_professional" href="/z/d/html/140668.html" rel="external">calculator 1</a>) [<a href="#rid21">21,36,42,43</a>]. The UISS incorporates the Eastern Cooperative Oncology Group (ECOG) performance status  (<a class="graphic graphic_table graphicRef72901" href="/z/d/graphic/72901.html" rel="external">table 2</a>) and Fuhrman histologic grade (1 through 4 [<a href="#rid24">24</a>]) into the TNM anatomic staging system. Using these variables, patients are characterized into distinct prognostic categories (low-, intermediate-, and high-risk) for disease recurrence postnephrectomy [<a href="#rid36">36</a>]. The value of this system has subsequently been validated [<a href="#rid21">21,42</a>]. </p><p class="headingAnchor" id="H7"><span class="h1">MOLECULAR MARKERS</span><span class="headingEndMark"> — </span>Although none of these factors has a clinical application for patient care, some markers have shown promise as prognostic markers in patients with clear cell RCC. Examples of markers that are potentially associated with a worse prognosis for patients with clear cell RCC include:</p><p class="bulletIndent1"><span class="glyph">●</span>Human B7 homolog 1 (B7H1) and 4 (B7H4) expression [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low levels of carbonic anhydrase IX (CAIX) [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High levels of the proliferation marker Ki-67 [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher levels of hypoxia-inducible factor (HIF)-1 alpha expression [<a href="#rid46">46</a>]; although at least one other study has suggested that patients with tumors that express HIF-1 alpha have a better prognosis than those with tumors that only express HIF-2 alpha [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/5195.html" rel="external">"Molecular biology and pathogenesis of von Hippel-Lindau disease", section on 'Hypoxia-inducible factor 1 and 2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of the U3 small nucleolar ribonucleoprotein (IMP3) [<a href="#rid48">48-50</a>]; which may extend to papillary and chromophobe tumors as well as clear cell RCCs [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deletion of chromosome 9p [<a href="#rid51">51-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations of tumor suppressor genes on chromosome 3p21, including mutations of breast cancer type 1 (BRCA1)-associated protein 1 (<em>BAP1</em>) and SET domain containing 2 (<em>SETD2</em>) [<a href="#rid55">55</a>]. In contrast, mutations involving polybromo-1 (<em>PBRM1</em>) had a more favorable prognosis [<a href="#rid56">56</a>], although in one study, the presence of both a <em>PBRM1</em> and a <em>BAP1</em> mutation conferred the worst prognosis [<a href="#rid56">56</a>].</p><p></p><p>Data from The Cancer Genome Atlas (TCGA) have elucidated potential molecular prognostic signatures using discovery (n = 193) and validation (n = 253) datasets. Main results suggested that worse survival is associated with upregulation of the fatty acid synthesis genes, acetyl-CoA carboxylase alpha (<em>ACACA</em>) and fatty acid synthase (<em>FASN</em>), as well as upregulation of multiple genes involved in the pentose phosphate pathway. On the other hand, better survival was associated with upregulation of adenosine monophosphate-activated kinase (AMPK) and multiple genes involved in the Krebs cycle and the mammalian (mechanistic) target of rapamycin (mTOR) pathway [<a href="#rid57">57</a>].</p><p>These data enabled the identification of four prognostic signatures for RCC, which appear to represent the metabolic states of the tumors and their variable use of key pathways and metabolites  (<a class="graphic graphic_figure graphicRef89968 graphicRef89913 graphicRef89969" href="/z/d/graphic/89968.html" rel="external">figure 2A-C</a>).</p><p>A gene expression panel that included 16 genes was developed to predict the risk of recurrence in a series of 942 patients who had undergone radical nephrectomy for stage I to III clear cell RCC [<a href="#rid58">58</a>]. This information was used to develop a recurrence score, which was then validated in a series of 626 patients. On multivariate analysis, this score was independently associated with an increased risk of tumor recurrence. Although this recurrence score provides additional information regarding the risk of recurrence, additional research to develop effective adjuvant therapies will be required if this panel is to be used to influence patient management.</p><p>In addition, germline genetic polymorphisms might affect the risk of recurrence in patients with localized RCC. In one large series, patients with MET polymorphism rs11762213 had an increased risk of recurrence after nephrectomy [<a href="#rid59">59</a>], and these results were validated in an independent cohort from TCGA [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H8"><span class="h1">PROGNOSTIC FACTORS IN STAGE IV DISEASE</span><span class="headingEndMark"> — </span>Although the prognosis for patients with recurrent or metastatic renal cell carcinoma (RCC) has historically been poor  (<a class="graphic graphic_figure graphicRef59133" href="/z/d/graphic/59133.html" rel="external">figure 1</a>), many studies performed in the era before effective therapy documented specific clinical features that were associated with longer survival; these factors remain pertinent in the targeted therapy era, reflecting the natural history of the disease [<a href="#rid61">61</a>]. One of the most commonly used prognostication systems is the one developed in the cytokines era by the Memorial Sloan Kettering Cancer Center (MSKCC) group, which integrates five adverse clinical and laboratory factors in previously untreated patients. Only three adverse factors are used in patients that were previously treated.</p><p>Contemporary trials in patients treated with agents targeting the vascular endothelial growth factor (VEGF) pathway have been analyzed to define prognostic factors relevant in the targeted therapy era [<a href="#rid62">62-65</a>]. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) compared baseline characteristics in 645 patients who were treated with several VEGF-targeted agents [<a href="#rid65">65</a>].</p><p>The six factors associated with poorer survival on multivariate analysis included  (<a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Karnofsky Performance Status (KPS) &lt;80  (<a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Time from original diagnosis to initiation of targeted therapy &lt;1 year</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin less than the lower limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium greater than the upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Neutrophil count greater than the upper limit of normal</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count greater than the upper limit of normal</p><p></p><p>These factors were subsequently validated in another cohort of 849 patients from the IMDC database [<a href="#rid66">66</a>]. This database was used to generate a similar model that can be applied to the outcome of second-line therapy following resistance to VEGF-targeted therapy [<a href="#rid67">67</a>], as well as to patients with non-clear cell RCC [<a href="#rid68">68</a>].</p><p>The relevance of the IMDC prognostic criteria in the era of frontline combination immunotherapy remains to be established. In the absence of alternative immunotherapy-based prognostic criteria, these criteria continue to be used in clinical trials to risk-stratify patients and, to some extent, by providers and clinical guidelines to direct therapy. Further details on such trials are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma", section on 'Risk stratification'</a>.)</p><p>Unlike other models, the IMDC model utilizes the same baseline prognostic factors for previously treated and untreated patients. The IMDC model was shown to improve prognostication compared with <strong>other </strong>prognostic models, such as the Cleveland Clinic Foundation (CCF) model [<a href="#rid69">69</a>], the International Kidney Cancer Working Group (IKCWG) model [<a href="#rid70">70</a>], the French model [<a href="#rid71">71</a>], and the MSKCC model [<a href="#rid72">72</a>].</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis for localized renal cell carcinoma</strong> – For patients presenting with localized renal cell carcinoma (RCC), the tumor, node, metastasis (TNM) staging system provides the primary prognostic information  (<a class="graphic graphic_figure graphicRef59133" href="/z/d/graphic/59133.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">table 1</a>). (See <a class="local">'Anatomic extent of disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional prognostic factors</strong> – Additional prognostic information can be provided by incorporating parameters such as performance status and histologic grade. These have been integrated with anatomic stage in the University of California, Los Angeles (UCLA) Integrated Staging System (UISS) (<a class="calc calc_professional" href="/z/d/html/140668.html" rel="external">calculator 1</a>). Ongoing research studies indicate that molecular markers may also be useful, though not commonly used in clinical practice. (See <a class="local">'Clinical factors'</a> above and <a class="local">'Molecular markers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors for metastatic disease</strong> – For patients with metastatic disease, multiple clinical parameters have been identified that are associated with prognosis. These are integrated into the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model  (<a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 3</a>), which has been useful in predicting outcomes in the contemporary era of therapy. (See <a class="local">'Prognostic factors in stage IV disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Rini BI, McKiernan JM, Chang SS, et al. Kidney. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.739.</li><li><a class="nounderline abstract_t">Verhoest G, Avakian R, Bensalah K, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009; 182:854.</a></li><li><a class="nounderline abstract_t">Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 2005; 173:33.</a></li><li><a class="nounderline abstract_t">Gilbert SM, Murphy AM, Katz AE, et al. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 2006; 68:287.</a></li><li><a class="nounderline abstract_t">Siddiqui SA, Frank I, Leibovich BC, et al. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol 2007; 177:59.</a></li><li><a class="nounderline abstract_t">Chevinsky M, Imnadze M, Sankin A, et al. Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. J Urol 2015; 194:310.</a></li><li><a class="nounderline abstract_t">Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979; 122:306.</a></li><li><a class="nounderline abstract_t">Ficarra V, Righetti R, D'Amico A, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001; 61:10.</a></li><li><a class="nounderline abstract_t">Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20.</a></li><li><a class="nounderline abstract_t">Cherrie RJ, Goldman DG, Lindner A, deKernion JB. Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982; 128:910.</a></li><li><a class="nounderline abstract_t">Anderson CB, Clark PE, Morgan TM, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology 2011; 78:99.</a></li><li><a class="nounderline abstract_t">Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014; 25:149.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370:1769.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722.</a></li><li><a class="nounderline abstract_t">Motzer RJ, McDermott DF, Escudier B, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 2022; 128:2085.</a></li><li><a class="nounderline abstract_t">Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763.</a></li><li><a class="nounderline abstract_t">Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010; 183:1309.</a></li><li><a class="nounderline abstract_t">Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol 2009; 182:2132.</a></li><li><a class="nounderline abstract_t">Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27:235.</a></li><li><a class="nounderline abstract_t">Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090.</a></li><li><a class="nounderline abstract_t">Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649.</a></li><li><a class="nounderline abstract_t">Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988; 61:1639.</a></li><li><a class="nounderline abstract_t">Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007; 177:430.</a></li><li><a class="nounderline abstract_t">Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655.</a></li><li><a class="nounderline abstract_t">Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 2007; 109:868.</a></li><li><a class="nounderline abstract_t">Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013; 37:1490.</a></li><li><a class="nounderline abstract_t">Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005; 104:511.</a></li><li><a class="nounderline abstract_t">Ficarra V, Novara G, Galfano A, et al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int 2009; 103:165.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530.</a></li><li><a class="nounderline abstract_t">Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107:1793.</a></li><li><a class="nounderline abstract_t">Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175:859.</a></li><li><a class="nounderline abstract_t">Fahn HJ, Lee YH, Chen MT, et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 1991; 145:248.</a></li><li><a class="nounderline abstract_t">Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol 2004; 172:2167.</a></li><li><a class="nounderline abstract_t">Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.</a></li><li><a class="nounderline abstract_t">Siemer S, Hack M, Lehmann J, et al. Outcome of renal tumors in young adults. J Urol 2006; 175:1240.</a></li><li><a class="nounderline abstract_t">Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.</a></li><li><a class="nounderline abstract_t">Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001; 58:141.</a></li><li><a class="nounderline abstract_t">Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348.</a></li><li><a class="nounderline abstract_t">Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48.</a></li><li><a class="nounderline abstract_t">Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109:205.</a></li><li><a class="nounderline abstract_t">Correa AF, Jegede O, Haas NB, et al. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J Clin Oncol 2019; 37:2062.</a></li><li><a class="nounderline abstract_t">Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001; 19:3792.</a></li><li><a class="nounderline abstract_t">Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22:3316.</a></li><li><a class="nounderline abstract_t">Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006; 5:206.</a></li><li><a class="nounderline abstract_t">Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004; 171:2461.</a></li><li><a class="nounderline abstract_t">Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:7388.</a></li><li><a class="nounderline abstract_t">Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435.</a></li><li><a class="nounderline abstract_t">Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7:556.</a></li><li><a class="nounderline abstract_t">Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008; 112:1471.</a></li><li><a class="nounderline abstract_t">Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008; 112:2676.</a></li><li><a class="nounderline abstract_t">La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010; 116:4696.</a></li><li><a class="nounderline abstract_t">Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008; 21:1.</a></li><li><a class="nounderline abstract_t">Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746.</a></li><li><a class="nounderline abstract_t">Presti JC Jr, Wilhelm M, Reuter V, et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002; 167:1464.</a></li><li><a class="nounderline abstract_t">Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19:3259.</a></li><li><a class="nounderline abstract_t">Kapur P, Peña-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159.</a></li><li><a class="nounderline abstract_t">Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43.</a></li><li><a class="nounderline abstract_t">Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol 2015; 16:676.</a></li><li><a class="nounderline abstract_t">Schutz FA, Pomerantz MM, Gray KP, et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 2013; 14:81.</a></li><li><a class="nounderline abstract_t">Hakimi AA, Ostrovnaya I, Jacobsen A, et al. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer 2016; 122:402.</a></li><li><a class="nounderline abstract_t">Heng DY, Choueiri TK. The evolving landscape of metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book 2012; :299.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004; 10:6302S.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552.</a></li><li><a class="nounderline abstract_t">Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115:776.</a></li><li><a class="nounderline abstract_t">Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794.</a></li><li><a class="nounderline abstract_t">Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141.</a></li><li><a class="nounderline abstract_t">Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015; 16:293.</a></li><li><a class="nounderline abstract_t">Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999.</a></li><li><a class="nounderline abstract_t">Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543.</a></li><li><a class="nounderline abstract_t">Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011; 17:5443.</a></li><li><a class="nounderline abstract_t">Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13:1460.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.</a></li></ol></div><div id="topicVersionRevision">Topic 2961 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Rini BI, McKiernan JM, Chang SS, et al. Kidney. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.739.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616244" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592020" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current TNM classification of renal cell carcinoma evaluated: revising stage T3a.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904438" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162000" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676433" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/469999" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aggressive surgical approach to renal cell carcinoma: review of 130 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474242" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984092" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surgical management and prognosis of renal cell carcinoma invading the vena cava.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7176049" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic implications of vena caval extension of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21550647" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24356626" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785224" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964934" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pazopanib versus sunitinib in metastatic renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35383908" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837991" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20171681" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19758615" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064974" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10737472" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11250993" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Improved prognostication of renal cell carcinoma using an integrated staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3349424" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17222604" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Grading systems in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7180965" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic significance of morphologic parameters in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262800" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prognostic ability of simplified nuclear grading of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24025520" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973740" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782313" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561319" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983701" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16469566" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic value of thrombocytosis in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988711" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15538224" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711737" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16515969" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Outcome of renal tumors in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454113" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489682" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12569375" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Metastatic renal carcinoma comprehensive prognostic system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15592023" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17149754" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31216227" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533107" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Validation of the ucla integrated staging system for patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15310775" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239274" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Significance of B7-H1 overexpression in kidney cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126876" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094421" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061835" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814207" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260086" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412154" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20629029" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906617" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124809" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11832771" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23620406" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23333114" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23792563" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comprehensive molecular characterization of clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979595" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219378" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26505625" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24451753" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The evolving landscape of metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15448021" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18720362" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19127560" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19826129" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312463" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681967" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23696129" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17577222" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21828239" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196373" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773181" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
